SIR GANGA RAM HOSPITAL
Old Rajinder Nagar, Rajinder Nagar, New Delhi, Delhi, 110060
Call Us on.
+91 9315125514 | +91 78386 82838
Mail Us
Dradityasarin@gmail.com
Old Rajinder Nagar, Rajinder Nagar, New Delhi, Delhi, 110060
+91 9315125514 | +91 78386 82838
Dradityasarin@gmail.com
Dr. Aditya Sarin is a Medical & Haemato-Oncologist treating all major solid tumours and blood cancers at Sir Ganga Ram Hospital, New Delhi — with every plan backed by molecular profiling and evidence-based protocols.
Click any cancer type to learn about symptoms, diagnosis, and Dr. Sarin's treatment approach for that specific cancer.
The most common cancer in Indian women. Early detection and precision subtype analysis — HR+, HER2+, or Triple Negative — are critical to choosing the right treatment strategy.
Often diagnosed at an advanced stage due to subtle early symptoms. BRCA testing and PARP inhibitor therapy have transformed outcomes in ovarian cancer management.
NSCLC and SCLC require very different approaches. Molecular profiling — EGFR, ALK, ROS1, PD-L1 — drives treatment choice between targeted therapy, immunotherapy, and chemo.
Highly preventable with HPV vaccination and Pap smear screening. When diagnosed, concurrent chemoradiation and immunotherapy (pembrolizumab) offer effective treatment pathways.
Head & neck cancers of the larynx and pharynx. HPV-associated oropharyngeal cancers respond well to concurrent chemo-radiation. Voice preservation is a key treatment goal.
Hepatocellular carcinoma (HCC) is often linked to Hepatitis B/C or cirrhosis. Sorafenib, lenvatinib, and immunotherapy combinations (atezolizumab + bevacizumab) have improved outcomes.
Colorectal cancer increasingly affects younger adults in India. MSI/MMR status, RAS/RAF mutations, and HER2 status guide choice between chemotherapy, targeted agents, and immunotherapy.
One of the most challenging cancers with late presentation. Gemcitabine + nab-paclitaxel, FOLFIRINOX, and BRCA-directed PARP inhibitors form the backbone of systemic treatment.
Oral cavity cancers are among the most prevalent cancers in Indian men, strongly linked to tobacco and betel nut use. Surgery plus adjuvant chemoradiation remains the standard approach.
Melanoma and non-melanoma skin cancers. Advanced melanoma now has excellent responses to BRAF-targeted therapy and immunotherapy combinations (anti-PD1 + anti-CTLA4).
Gastric adenocarcinoma often presents at an advanced stage. HER2 status, PD-L1 expression, and MSI testing are now standard before initiating trastuzumab or immunotherapy-based regimens.
The same rigorous, personalised methodology — regardless of tumour type.
NGS, IHC, and biomarker testing on every tumour before treatment starts — not after failure.
Complex cases presented to a multidisciplinary board of surgical, radiation, and medical oncologists.
Treatment aligned with ESMO, ASCO, and NCCN guidelines — updated with every major trial.
Pain management, nutritional support, and psychological guidance alongside active treatment.
A structured, patient-first process that never loses sight of the individual behind the diagnosis.
In-depth history, review of prior reports, and ordering of any missing investigations or molecular tests.
Tumour board discussion and personalised plan based on your cancer's molecular fingerprint.
Chemotherapy, targeted therapy, immunotherapy, or combination — with close cycle-by-cycle monitoring.
Regular surveillance, response assessment, and long-term support after treatment ends.
Book a consultation with Dr. Aditya Sarin. Bring your reports, scans, and biopsy results — and leave with clarity.